Neuberger Berman Group
XLRN

Neuberger Berman Group’s Acceleron Pharma XLRN Stock Holding History

Neuberger Berman Group’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-24,075
Closed -$1.05M – 1640
2018
Q4 		$1.05M Buy
+24,075
New +$1.2M ﹤0.01% 1106
2018
Q1 		– Sell
-10,375
Closed -$440K – 1772
2017
Q4 		$440K Buy
+10,375
New +$389K ﹤0.01% 1430

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Neuberger Berman Group's XLRN Position: Q1 2019 in Review

Neuberger Berman Group sold out of Acceleron Pharma (XLRN) in Q1 2019, closing a stake of 24,075 shares — an estimated $1.05M sold.

Neuberger Berman Group first reported a position in XLRN in Q4 2017 and held it in 2 quarters. The position peaked at $1.05M in Q4 2018. 171 funds tracked by Wall St. Rank hold XLRN as of Q1 2019.

  • Neuberger Berman Group reported no remaining Acceleron Pharma position as of Q1 2019 after selling out during the quarter.
  • Neuberger Berman Group sold 24,075 Acceleron Pharma shares in Q1 2019, an estimated $1.05M.
  • Neuberger Berman Group first reported a position in Acceleron Pharma in Q4 2017 and held it in 2 quarters.
  • Neuberger Berman Group's Acceleron Pharma position peaked at $1.05M in Q4 2018.
  • 171 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2019.

Based on Neuberger Berman Group's 13F filing for Q1 2019, filed 13 May 2019.